Loading
Convergent Therapeutics
Convergent Therapeutics attaches an alpha-emitting isotope to an antibody that homes in on prostate cancer cells, for men whose disease has progressed after standard radioligand treatment. Its lead medicine has reported mid-stage trial results.
Overview
Convergent Therapeutics develops alpha radioantibodies: antibodies that deliver alpha-emitting payloads directly into cancer cells while limiting exposure of healthy tissue. The lead candidate CONV01-α is a PSMA-directed actinium-225 radioantibody for metastatic castration-resistant prostate cancer in patients previously treated with 177Lu-PSMA. In June 2026 the company presented what it described as the largest prospective phase 2 dataset for an alpha radiopharmaceutical at ASCO 2026, reporting anti-tumour activity, durability and favourable tolerability in Lu-PSMA-exposed mCRPC.
Notes
- The Business Wire releases (ASCO 2026 data, Series A) returned HTTP 403, so funding is omitted; trade press headlines report a USD 90 million Series A (2023) and a USD 40 million extension, unverified here. The domains convergenttx.com and convergenttherapeutics.com are parked; convergentrx.com blocks scripted requests but was fetched via WebFetch.
Connected
6Similar pages
- CompanyARTBIO
Shares Targeted alpha therapy, PSMA, Prostate cancer.
- TechnologyAuger-electron therapy
Shares Radio-antibody & radio-ADC, Targeted alpha therapy, PSMA.
- TrialA Single-Arm, Blinded, Fluorescent PSMA Histopathology Trial of AS1986NS
Shares PSMA, Prostate cancer.
- CompanyActinium Pharmaceuticals
Shares Radio-antibody & radio-ADC, Targeted alpha therapy, Prostate cancer.
- PersonClemens Kratochwil
Shares Targeted alpha therapy, PSMA, Prostate cancer.
- TrialA Study of TRC003 in the Treatment of Patients With Progressive PSMA-positive mCRPC
Shares PSMA, Prostate cancer.
- TrialPSMA-PET to Guide Prostatectomy
Shares PSMA, Prostate cancer.
- TrialA Clinical Trial Evaluating the Safety of TD001 In Patients With PSMA-Expressing Metastatic Prostate Cancer
Shares PSMA, Prostate cancer.
cancers
fronts
technologies
targets
trials
Sources
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
convergentrx.com · 1
A source that has moved or gone is reported by the weekly link check. /audit/